Detection of early stage cancers and assessment of proliferative potensitals of cancers through measurement of urinary diacetylsperime

通过测量尿二乙酰精液检测早期癌症并评估癌症的增殖潜力

基本信息

批准号：
16590471
负责人：
HIRAMATSU Kyoko
金额：
$ 2.24万
依托单位：
Tokyo Metropolitan Organization For Medical Research
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2004
资助国家：
日本
起止时间：
2004 至 2005
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16590471/
关键词：
polyamine ELISA tumor marker polyamines tumor marker 癌臨床検査生体分子

项目摘要

Excretion of N^1,N^<12>-diacetylspermine (DiAcSpm) in the urine is increased in patients with various neoplastic diseases. We developed an ELISA system for easy determination of urinary DiAcSpm level using a highly specific antibody against DiAcSpm, and analyzed DiAcSpm in the urine of a number of cancer patients. The sensitivity of urinary DiAcSpm for colon cancer patients was 75.8% (with 0.25μmol/g creatinine, that represents mean + 2S.D. for 52 healthy controls, as a cut-off value), which was markedly higher than that of serum CEA (39.5%), and CA19-9 (14.1%). The sensitivity of urinary DiAcSpm for 83 breast cancer patients (60.2%) was higher than that of CEA (37.3%) and CA15-3 (37.3%). We further demonstrated that DiAcSpm was elevated above the cut-off value in 60% of colorectal cancer patients at earlier clinical stages, namely stage 0 and stage I. Patients whose DiAcSpm was lower than the cut-off value before surgery (25% of the total patients) rarely died of cancer within 1.5 year period after surgery, during which about 10% of the total patients died. Prognosis of patients whose DiAcSpm value was higher than 3 times the cut-off value was significantly poorer than patients with lower DiAcSpm value. This indicate that DiAcSpm value before operation is well correlated with the prognosis of a patient. DiAcSpm recovered to a normal level after a successful treatment of cancer patients including prostate cancer, colon cancer and brain tumor, while the prognosis was poor when DiAcSpm level remained far above the normal limit after apparently effective treatment. Urinary DiAcSpm may thus be considered a novel high performance tumor marker useful in tumor diagnosis, in judging the effectiveness of a treatment and in foreseeing prognosis of patients.

各种肿瘤疾病患者的尿液中N^1，N^<12> -Diacetylspermine（DIACSPM）的排泄增加。我们开发了一种ELISA系统，可轻松地使用针对DIACSPM的高特异性抗体确定尿液DIACSPM水平，并在许多癌症患者的尿液中分析DIACSPM。尿DIACSPM对结肠癌患者的敏感性为75.8％（0.25μmol/g肌酐，表示为52个健康对照，作为截止值的平均值 + 2s.d.ds.d.ds.ds.ds.ds.ds.ds.ds.ds.ds.ds.d. cea（39.5％）和CA19-9-9-9（14.1％）的敏感性。 83例乳腺癌患者（60.2％）的尿液DIACSPM的敏感性高于CEA（37.3％）和CA15-3（37.3％）。我们进一步证明，在早期的临床阶段，60％的结直肠癌患者的临界值高于临界值，即DIACSPM低于手术前的DIACSPM低于临界值的患者（25％的总患者）在手术后1.5年内很少在癌症中死亡，在手术后1.5年，在总患者死亡的情况下约10％。 DIACSPM值高于截止值的3倍的患者的预后明显比DIACSPM值较低的患者差。这表明操作前的DIACSPM值与患者的预后良好相关。成功治疗包括前列腺癌，结肠癌和脑肿瘤在内的癌症患者后，DIACSPM恢复到了正常水平，而当DIACSPM水平在显然有效治疗后，预后较差。因此，尿液DIACSPM可以被认为是一种新型的高性能肿瘤标记物，可用于肿瘤诊断，可判断治疗的有效性和预见患者的预后。